Chemistry: analytical and immunological testing – Biospecific ligand binding assay
Reexamination Certificate
2003-11-03
2009-11-10
Li, Q. Janice (Department: 1633)
Chemistry: analytical and immunological testing
Biospecific ligand binding assay
C436S063000, C436S086000, C436S536000
Reexamination Certificate
active
07615380
ABSTRACT:
This invention demonstrates that KRC molecules have multiple important functions as modulating agents in regulating a wide variety of cellular processes including: inhibiting NFkB transactivation, increasing TNF-alpha induced apoptosis, inhibiting JNK activation, inhibiting endogenous TNF-alpha expression, promoting immune cell proliferation and immune cell activation (e.g., in Th1 cells), activating IL-2 expression e.g., by activating the AP-1 transcription factor, and increasing actin polymerization. The present invention also demonstrates that KRC interacts with TRAF. Furthermore, the present invention demonstrates that KRC physically interacts with the c-Jun component of AP-1 to control its degradation Methods for identifying modulators of KRC activity are provided. Methods for modulating an immune response using agents that modulate KRC activity are also provided.
REFERENCES:
patent: WO-2004/060304 (2004-07-01), None
Guo et al, Proc Natl Acad Sci 101(25):9205-9210, 2004.
Hult and Berglund, Curr Opin Biotechnol 14:395-400, 2003.
Kuroiwa et al, Nature Genetics 36(7):775-80, 2004.
Moreadith et al, J. Mol. Med. 75(3): 208-216, 1997
Polejaeva et al, Theriogenology, 53(1):117-126, 2000.
Rulicke et al, Experimental Physiology 85: 589-601, 2000.
Bishop, Reprod. Nutr. Dev. 36: 607-618, 1998.
Mullins et al, Journal of Clinical Investigation 97(7): 1557-1560, 1996.
Houdebine, J. Biotech. 34: 269-287, 1994.
Pearson, Nature 415(6867):8-9, 2002.
Mullins et al, Hypertension 22: 630-633, 1993.
Denning, Nat. Biotech. 19:559-562, 2001.
Humpherys et al, Science 293:95-97, 2001.
Wall et al, J Dairy Sci. 80:2213-2224, 1997.
Yanagimachi, Mol. Cell Endocrinol. 187:241-248, 2002.
Kappel et al, Current Opinion in Biotechnology 3: 548-553, 1992.
Wall, Theriogenology 45: 57-68, 1996.
Cameron, Molec. Biotech. 7: 253-265, 1997.
Sigmund, Arteroscler. Throm. Vasc. Biol. 20: 1425-1429, 2000.
Anders and Schlondorff, Exp. Nephrol. 8: 181-193, 2000.
Schalkwyk et al, Genes Brain Behav, 6:299-303, 2007.
Gerlai, Trends Neurosci, 19: 177-181, 1996.
Deonarain, Expert Opin. Ther. Pat. 8: 53-69, 1998.
Verma and Somia, Nature 389: 239-242, 1997.
Eck et al, Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY., pp. 77-101, 1996.
Gorecki, Expert Opin. Emerging Drugs 6(2): 187-98, 2001.
Cleland et al, Current Opinion in Biotechnology 12: 212-219, 2001.
Rudinger, in J.A. Parsons, ed. “Peptide hormones”, University Park Press, 1976.
Ngo et al., In Merz et al., ed. “The protein folding problem and tertiary structure prediction”, Birkhauser, 1994.
Wells, Biochemistry 29:8509-8517, 1990.
Skolnick et al, Trends in Biotech. 18:34-39, 2000.
Bork, Genome Research 10:398-400, 2000.
Doerks et al, Trends in Genetics 14:248-250, 1998.
Smith et al, Nature Biotechnology 15:1222-1223, 1997.
Affolter, et al., “Nuclear interpretation of Dpp signaling in Drosophila,”EMBO J.,vol. 20(13):3298-305 (2001).
Allen, et al., “The kappa B transcriptional enhancer motif and signal sequences of V(D)J recombination are targets for the zinc finger protein HIVEP3/KRC: a site selection amplification binding study,”BMC Immunol.,vol. 22;3(1):10 (2002).
Allen, et al., “Downregulation of KRC induces proliferation, anchorage independence, and mitotic cell death in HeLa cells,”Exp Cell Res.,vol. 260(2):346-56 (2000).
Allen, et al., “Developmental anomalies and neoplasia in animals and cells deficient in the large zinc finger protein KRC,”Genes Chromosomes Cancer,vol. 35(4):287-98 (2002).
Allen, Carl E. et al., “KRC controls cell growth by regulating the transcription of c-myc,” Presented at the American Society of Biochemistry and Molecular Biology Annual Meeting, Washington, D.C., p. A1391, Abstract No. 473 (1998).
Angel P. et al., “Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor,”Cell,vol. 49(6):729-39 (1987).
Arch, et al., “Tumor necrosis factor receptor-associated factors (TRAFs)—a family of adapter proteins that regulates life and death,”Genes Dev.,vol. 12(18):2821-30 (1998).
Arias, et al., “Activation of cAMP and mitogen responsive genes relies on a common nuclear factor,”Nature,vol. 370(6486):226-9 (1994).
Arora, et al., “The Drosophila schnurri gene acts in the Dpp/TGF beta signaling pathway and encodes a transcription factor homologous to the human MBP family,”Cell,vol. 81(5)781-90 (1995).
Bachmeyer, et al., “Regulation by phosphorylation of the zinc finger protein KRC that binds the kappaB motif and V(D)J recombination signal sequences,”Nucleic Acids Res.,vol. 27(2):643-8 (1999).
Behre, et al., “C-Jun is a JNK-independent coactivator of the PU.1 transcription factor,”J. Biol. Chem.,vol. 274(8):4939-46 (1999).
Berhrens, et al., “Jun N-terminal kinase 2 modulates thymocyte apoptosis and T cell activation through c-Jun and nuclear factor of activated T cell (NF-AT),”Proc. Natl. Acad. Sci. USA,vol. 98(4):1769-74 (2001).
Bianchi, et al., “Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity,”Nature,vol. 404(6778):617-21 (2000).
Binetruy, et al., “Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain,”Nature,vol. 351(6322):122-7 (1991).
Borden, et al., “The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML,”EMBO J.,vol. 14(7):1532-41 (1995).
Cao, et al., “TRAF6 is a signal transducer for interleukin-1,” Nature, vol. 383(6599):443-6 (1996).
Castellanos, et al., “Expressions of the leukocyte early activation antigen CD69 is regulated by the transcription factor AP-1,”J. Immunol.,vol. 159(11)5463-73 (1997).
Claret, et al., “A new group of conserved coactivators that increase the specificity of AP-1 transcription factors,”Nature,vol. 383(6599):453-7 (1996).
Cohn, et al., “Characterization of Sp1, AP-1, CBF and KRC binding sites and minisatellite DNA as functional elements of the metastasis-associated mts1/S100A4 gene intronic enhancer,”Nucleic Acids Res.,vol. 29(16):3335-46 (2001).
Dai, et al., “The zinc finger protein schnurri acts as a Smad partner in mediating the transcriptional response to decapentaplegic,”Dev. Biol.,vol. 227(2):373-87 (2000).
Deng, et al., “c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK,”Nature,vol. 371(6493):171-5 (1994).
Dong, et al., “JNK is required for effector T-cell function but not for T-cell activation.”Nature,vol. 405(6782):91-4 (2000).
Dumitru, et al., “TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway,”Cell,vol. 103(7):1071-83 (2000).
Durand, et al., “A 275 basepair fragment at the 5′ end of the interleukin 2 gene enhances expression from a heterologous promoter in response to signals from the T cell antigen receptor,”J. Exp. Med.,vol. 165(2):395-407 (1987).
Ghosh, et al., “NF-KappaB and Rel Proteins: Evolutionarily conserved mediators of immune responses,” Annu. Rev. Immunol., vol. 16:226-260 (1998).
Grieder, et al., “Schnurri is required for Drosophila Dpp signaling and encodes a zinc finger protein similar to the mammalian transcription factor PRDII-BF1,”Cell,vol. 81(5):791-800 (1995).
Hicar, et al., “Embryonic expression and regulation of the large zinc finger protein KRC,”Genesis,vol. 33(1):8-20 (2002).
Hicar, et al., “Structure of the human zinc finger protein HIVEP3: molecular cloning, expression, exon-intron structure, and comparison with paralogous genes HIVEP1 and HIVEP2,”Genomics,vol. 71(1):89-100 (2001).
Himes, et al., “High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 p
Glimcher Laurie H.
Oukka Mohamed
Hill Kevin K.
Lahive & Cockfield LLP
Li Q. Janice
President and Fellows of Harvard College
Williams, Esq. Megan E.
LandOfFree
Methods for modulating an immune response by modulating KRC... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulating an immune response by modulating KRC..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulating an immune response by modulating KRC... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4091771